These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32902774)

  • 1. Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study.
    Peng XV; McCrimmon RJ; Shepherd L; Boss A; Lubwama R; Dex T; Skolnik N; Ji L; Avogaro A; Blonde L
    Diabetes Ther; 2020 Nov; 11(11):2629-2645. PubMed ID: 32902774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
    Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
    Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study.
    Peng XV; Ayyagari R; Lubwama R; Shi L; Price-Haywood EG; Hollander P; Fonseca V
    Diabetes Ther; 2020 Apr; 11(4):995-1005. PubMed ID: 32112204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists.
    Rosenstock J; Ampudia-Blasco FJ; Lubwama R; Peng XV; Boss A; Shi L; Fonseca V
    Diabetes Obes Metab; 2020 Dec; 22(12):2295-2304. PubMed ID: 32729183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin.
    Blonde L; Raccah D; Lew E; Meyers J; Nikonova E; Ajmera M; Davis KL; Bertolini M; Guerci B
    Diabetes Ther; 2018 Jun; 9(3):1169-1184. PubMed ID: 29675797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA.
    Blonde L; Meneghini L; Peng XV; Boss A; Rhee K; Shaunik A; Kumar S; Balodi S; Brulle-Wohlhueter C; McCrimmon RJ
    Diabetes Ther; 2018 Jun; 9(3):1347-1358. PubMed ID: 29600507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs).
    Desouza C; Kirk AR; Mangla KK; Wolden ML; Lingvay I
    BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33376084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).
    Polonsky WH; Arora R; Faurby M; Fernandes J; Liebl A
    Diabetes Ther; 2022 Jan; 13(1):175-187. PubMed ID: 34918213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiation of the Fixed Combination IDegLira in Patients with Type 2 Diabetes on Prior Injectable Therapy: Insights from the EASY French Real-World Study.
    Tramunt B; Disse E; Chevalier N; Bordier L; Cazals L; Dupuy O; Marre M; Matar O; Meyer L; Noilhan C; Sanz C; Valensi P; Velayoudom FL; Gautier JF; Gourdy P
    Diabetes Ther; 2022 Dec; 13(11-12):1947-1963. PubMed ID: 36331712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Real-World, Observational Study of the Initiation, Use, and Effectiveness of Basal-Bolus or Premixed Insulin in Japanese People with Type 2 Diabetes.
    Miyoshi H; Baxter M; Kimura T; Hattori M; Morimoto Y; Marinkovich D; Tamiwa M; Hirose T
    Diabetes Ther; 2021 May; 12(5):1341-1357. PubMed ID: 33730337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study.
    Lingvay I; Kirk AR; Lophaven S; Wolden ML; Shubrook JH
    Diabetes Ther; 2021 Mar; 12(3):879-896. PubMed ID: 33594582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes in Adriatic Region Countries: ENSURE-ADR, a Real-World Study.
    Đekić D; Bojić M; Janež A; Klobučar S; Hadžimušović IG; Ković T; Mihalevska S
    Diabetes Ther; 2023 Jul; 14(7):1217-1229. PubMed ID: 37211579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone.
    Wright EE; Roberts GJ; Chuang JS; Nabutovsky Y; Virdi N; Miller E
    Diabetes Technol Ther; 2024 May; ():. PubMed ID: 38669474
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin.
    Chou HW; Cheng KP; Lin AC; Hung HC; Lin CH; Wang CC; Wu HT; Ou HY
    Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36559020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.
    Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H
    Diabetes Ther; 2018 Jun; 9(3):1149-1167. PubMed ID: 29675798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study.
    Candido R; Nicolucci A; Larosa M; Rossi MC; Napoli R;
    Nutr Metab Cardiovasc Dis; 2023 Nov; 33(11):2294-2305. PubMed ID: 37679243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study.
    Hoog M; Paczkowski R; Huang A; Halpern R; Buysman E; Stackland S; Zhang Y; Wangia-Dixon R
    Diabetes Ther; 2023 Nov; 14(11):1947-1958. PubMed ID: 37740872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resource use and outcomes associated with initiation of injectable therapies for patients with type 2 diabetes mellitus.
    Brice R; Shelley S; Chaturvedi P; Glah D; Ashley D; Hadi M
    Drugs Context; 2015; 4():212269. PubMed ID: 25657811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating Glycemic Control in Patients with Type 2 Diabetes Suboptimally Controlled on Basal Insulin: UK ATTAIN Real-World Study.
    Jude EB; Nixon M; O'Leary C; Myland M; Gooch N; Shaunik A; Lew E
    Diabetes Ther; 2019 Oct; 10(5):1847-1858. PubMed ID: 31321748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study.
    Hoog M; Maldonado JM; Wangia-Dixon R; Halpern R; Buysman E; Gremel GW; Huang A; Konig M
    Diabetes Ther; 2024 Apr; 15(4):855-867. PubMed ID: 38427164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.